PureTech Health PLC

PureTech Health PLC

Health CarePharmaceuticals and Biotechnology
  • Price (USD)27.50
  • Today's Change0.43 / 1.59%
  • Shares traded1.43k
  • 1 Year change+17.52%
  • Beta--
Data delayed at least 15 minutes, as of May 30 2023 15:46 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

PureTech Health plc is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company's R&D engine has developed 27 therapeutics and therapeutic candidates, including two (Plenity and EndeavorRx) that have received both United States (US) Food and Drug Administration (FDA) clearance and European marketing authorization. The Company's pipeline includes LYT-100, LYT-200, LYT-300, LYT-310 and LYT-503/IMB-150. LYT-100 (deupirfenidone) is being advanced for the potential treatment of conditions involving inflammation and fibrosis. It is developing LYT-200 for the treatment of metastatic/locally advanced solid tumors that have poor survival rates, including urothelial and head and neck cancers. LYT-300 is an oral prodrug of allopregnanolone, which is being advanced for the potential treatment of anxiety disorders and postpartum depression.

  • Revenue in USD (TTM)15.62m
  • Net income in USD-50.35m
  • Incorporated2015
  • Employees111.00
  • Location
    PureTech Health PLC6 Tide Street, Suite 400BOSTON 02210United StatesUSA
  • Phone+1 (617) 482-2333
  • Fax+1 (617) 482-3337
  • Websitehttps://puretechhealth.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Lyell Immunopharma Inc84.20m-181.93m721.37m274.00--0.9203--8.57-0.731-0.7310.33563.140.0862----307,281.00-18.64---19.35-------216.09------0.00--695.15--26.82------
Arcturus Therapeutics Holdings Inc281.04m111.27m721.72m170.,653,177.0027.38-25.2036.16-31.59----39.59-118.84----0.00--1,566.7973.78104.59--98.45--
4D Molecular Therapeutics Inc2.21m-109.84m726.44m137.00--2.68--329.15-3.38-3.380.0686.580.0078----15,764.29-38.61-31.26-40.26-33.58-----4,976.80-526.63----0.00---82.65-11.58-50.73--82.30--
Bicycle Therapeutics PLC (ADR)15.50m-124.22m727.65m236.00--2.99--46.95-4.17-4.170.52088.100.0349--0.6265,673.73-27.97-26.32-31.06-29.28-----801.45-492.29----0.1112--23.6547.67-68.69--76.36--
Dyne Therapeutics Inc0.00-176.70m738.21m122.00--3.05-----3.33-3.330.004.150.00----0.00-52.25---55.96--------------0.00-------12.60------
Anavex Life Sciences Corp0.00-52.74m753.41m38.00--5.15-----0.6768-0.67680.001.810.00----0.00-33.02-46.07-35.47-51.22------------0.00-------26.56------
PureTech Health PLC (ADR)15.62m-50.35m770.14m111.00--1.39--49.31-1.75-1.750.542719.460.019--2.08140,702.70-4.505.21-5.586.53-----237.32265.77---2.460.07890.00-10.1843.8616.85--0.046--
Avidity Biosciences Inc9.66m-192.15m771.93m186.00--1.38--79.89-3.36-3.360.16757.890.0187----51,946.24-37.13---40.20-------1,988.76------0.00---1.09---47.44------
Ambrx Biopharma Inc - ADR5.81m-70.65m773.76m66.00--4.24--133.11-1.77-1.770.14273.31------88,075.76-------------1,215.40------0.00---0.7109---14.57------
Collegium Pharmaceutical Inc524.95m-29.36m779.42m207.00--4.336.311.48-0.8616-0.861615.395.200.42674.993.042,535,986.00-2.390.4411-3.510.789746.3246.84-5.590.70131.131.140.81620.0067.5674.74-134.96--256.95--
Regenxbio Inc109.64m-270.27m791.08m401.00--1.70--7.22-6.25-6.252.5310.700.1237--4.78273,426.40-30.48-7.65-35.08-8.5160.8483.86-246.50-26.08---20.100.00---76.0361.09-319.27--33.82--
Cogent Biosciences Inc0.00-148.19m796.73m138.00--4.94-----2.32-2.320.003.150.00----0.00-63.05-44.58-68.76-50.10-------881.92----0.00-------94.04--49.73--
Allogene Therapeutics Inc234.00k-351.49m806.50m359.00--1.36--3,446.60-2.44-2.440.00164.060.0003----651.81-41.07-29.66-43.53-31.41-----150,207.70-3,191.05----0.00---99.37---29.43------
Enliven Therapeutics Inc0.001.49m806.67m6.00127.201.43384.31--0.15420.15420.0013.710.00----0.001.60-45.581.69-49.29------------0.00------102.9046.43----
Twist Bioscience Corp227.84m-212.61m823.49m989.00--1.17--3.61-3.76-3.764.0312.330.2433.166.38230,376.10-22.67-35.74-24.74-39.8341.3332.59-93.32-136.186.23--0.00--53.8380.02-43.24--72.89--
Data as of May 30 2023. Currency figures normalised to PureTech Health PLC's reporting currency: US Dollar USD

Institutional shareholders

0.29%Per cent of shares held by top holders
HolderShares% Held
AWM Investment Co., Inc.as of 31 Mar 202370.00k0.25%
Jane Street Capital LLCas of 31 Mar 20239.63k0.04%
UBS Financial Services, Inc.as of 31 Mar 202320.000.00%
UBS Securities LLCas of 31 Mar 20231.000.00%
Migdal Mutual Funds Ltd.as of 28 Feb 20220.000.00%
Old Mission Capital LLCas of 31 Mar 20230.000.00%
More ▼
Data from 28 Feb 2023 - 31 Mar 2023Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.